Particle Analytical joins Kymos Group
After 25 years of scientific specialization and steady growth, Particle Analytical begins a new chapter by joining Kymos Group, a fast-growing European contract research organization (CRO) headquartered in Barcelona.
This integration represents a natural evolution for both companies, built on a shared commitment to scientific excellence, regulatory rigor, and long-term client partnerships.
25 years building a reference in solid state analysis
Founded in 2000 by Søren Lund Kristensen, Particle Analytical has established itself as one of the few global reference laboratories specialized in solid state characterization and particle analysis for the pharmaceutical industry.
From its facilities at DTU Science Park in Denmark, the company has supported pharmaceutical and biotech companies worldwide with advanced analytical services critical for drug development, quality control, and regulatory submissions.
Operating under European GMP certification and successfully inspected by the FDA, Particle Analytical has built a strong reputation for delivering reliable, high-quality data aligned with the most demanding regulatory standards.
Reflecting on this milestone, Søren Lund Kristensen comments:
“This integration marks the culmination of 25 years in the pharmaceutical industry. Together with my team, we have built one of the few worldwide reference companies specialized in solid state analysis. Joining Kymos Group will allow us to grow in areas where we are not yet present and strengthen our capacity to invest in new technologies.”
A new growth platform within Kymos Group
By joining Kymos Group, Particle Analytical gains access to a broader international infrastructure and complementary scientific expertise.
Kymos Group, founded in 2001 in Barcelona, has grown into a dynamic European CRO with laboratories in Spain, Italy, and Germany, and a recently established affiliate in South Korea. Over the past years, the Group has experienced sustained double-digit growth, supported by continuous investment in technology and innovation.
Kymos provides a wide range of analytical and bioanalytical services to the biopharmaceutical industry, with strong expertise in:
- Small molecules
- Biologics
- TIDES (peptides and oligonucleotides)
- Advanced therapies
Approximately half of the Group’s activity is focused on biologics and advanced therapies, positioning Kymos at the forefront of innovation-driven pharmaceutical development.
The integration of Particle Analytical strengthens the Group in a highly specialized and strategically relevant area solid state and particle characterization — further consolidating its positioning as a one-stop-shop analytical partner.
Strengthening scientific capabilities across Europe
For clients, this integration means access to:
- Broader scientific expertise within a single group
- Enhanced technical capabilities in solid state analysis
- Greater geographical coverage across Europe
- Continued compliance with the highest regulatory standards
Particle Analytical will continue operating with the same team, the same scientific rigor, and the same commitment to quality that have defined its success for 25 years — now supported by the scale, infrastructure, and international reach of Kymos Group.
This new chapter reinforces a shared ambition: to build a strong, competitive European analytical platform capable of delivering excellence in an increasingly complex and regulated pharmaceutical environment.
